Si-Tahar M, Merlin D, Sitaraman S, Madara J L
Epithelial Pathobiology Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Gastroenterology. 2000 Jun;118(6):1061-71. doi: 10.1016/s0016-5085(00)70359-3.
BACKGROUND & AIMS: Epithelial cells participate in immune regulation and mucosal integrity by generating a range of biologically active mediators. In the intestine, little is known about the potential endogenous anti-inflammatory molecules. Secretory leukocyte proteinase inhibitor (SLPI) is a major serine proteinase inhibitor, a potent antibiotic, and thus a potential anti-inflammatory molecule, although it is not known if it is secreted by intestinal epithelial cells.
We show, by reverse-transcription polymerase chain reaction, the presence of SLPI messenger RNA in human model intestinal epithelial cell lines (Caco2-BBE, T84, and HT29-Cl.19A) and human jejunum and colon biopsy specimens. The polymerase chain reaction product was cloned and sequenced and is identical to that of SLPI isolated previously from the human parotid gland.
As analyzed by enzyme-linked immunosorbent assay, the constitutive secretion of SLPI occurs in a markedly polarized manner toward the apical surface and is enhanced by inflammatory mediators including tumor necrosis factor alpha and interleukin 1beta (approximately 3.5-fold increase over control value). SLPI release is also stimulated by activation of protein kinase C isoenzymes, but not by activation of adenosine 3',5'-cyclic monophosphate- or Ca(2+)-regulated signaling molecules. SLPI protein is detectable in intestinal lavage fluids collected from normal adult humans. Recombinant SLPI attenuates digestive enzyme (trypsin)- or leukocyte proteinase (elastase)-induced permeability alteration of a model epithelia in a dose-dependent manner. Moreover, SLPI exhibits an antibacterial activity against at least one major intestinal pathogen, Salmonella typhimurium. In contrast, SLPI does not influence epithelial barrier integrity as assessed by transepithelial conductance measurements or electrogenic ion transport.
These results establish that human intestinal epithelium expresses and apically secretes SLPI, a molecule that may significantly contribute to the protection against attack from inflammatory cells and digestive enzymes, as well as against microbial infection.
上皮细胞通过产生一系列生物活性介质参与免疫调节和黏膜完整性维持。在肠道中,关于潜在的内源性抗炎分子知之甚少。分泌型白细胞蛋白酶抑制剂(SLPI)是一种主要的丝氨酸蛋白酶抑制剂,具有强效抗菌作用,因此是一种潜在的抗炎分子,不过尚不清楚它是否由肠道上皮细胞分泌。
我们通过逆转录聚合酶链反应显示,人模型肠道上皮细胞系(Caco2 - BBE、T84和HT29 - Cl.19A)以及人空肠和结肠活检标本中存在SLPI信使核糖核酸。聚合酶链反应产物被克隆并测序,与先前从人腮腺分离的SLPI相同。
通过酶联免疫吸附测定分析,SLPI的组成性分泌以明显的极性方式朝向顶端表面发生,并且被包括肿瘤坏死因子α和白细胞介素1β在内的炎症介质增强(比对照值增加约3.5倍)。蛋白激酶C同工酶的激活也刺激SLPI释放,但腺苷3',5'-环磷酸或Ca(2 +)调节的信号分子的激活则无此作用。在从正常成年人收集的肠道灌洗液中可检测到SLPI蛋白。重组SLPI以剂量依赖性方式减轻消化酶(胰蛋白酶)或白细胞蛋白酶(弹性蛋白酶)诱导的模型上皮通透性改变。此外,SLPI对至少一种主要肠道病原体鼠伤寒沙门氏菌具有抗菌活性。相比之下,通过跨上皮电导测量或电生性离子转运评估,SLPI不影响上皮屏障完整性。
这些结果表明,人肠道上皮表达并向顶端分泌SLPI,该分子可能对抵御炎症细胞和消化酶的攻击以及微生物感染有显著作用。